Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA)

NCT03246269 | Completed

• 1 other identifier: MoCA-Norm
• Study Type: observational
• Target: 334
• Locations: 0 countries
• Sites: N/A

Brief Summary

This observational cohort study in healthy volunteers establishes normative data for the German version of the Montreal Cognitive Assessment (MoCA) and investigates the possible impacts of demographics on the MoCA total score.

Conditions

Cognitive Impairment; Cognitive Decline; Cognition Disorders; Cognitive Symptom; Cognitive Change; Cognitive Deterioration; Cognitive Abnormality; Cognitive Impairment, Mild; Cognition Disorders in Old Age; Dementia; Dementia Alzheimers; Dementia, Alzheimer Type; Dementia, Mild; Dementia of Alzheimer Type

Outcome Measures

Primary Outcomes (1)

• Montreal Cognitive Assessment (MoCA) - German version

  Total score of the MoCA

  Baseline

Secondary Outcomes (3)

• Mini-Mental State Examination (MMSE)

  Baseline

• Geriatric Depression Scale (GDS)

  Baseline

• Consortium to Establish a Registry for Alzheimer's Disease - Neuropsychological Assessment Battery (CERAD-NAB)

  Baseline

Study Arms (1)

MoCA cohort

The German MoCA is administered once to all study participants.

Diagnostic Test: MoCA

Interventions

MoCA DIAGNOSTIC_TEST

MoCA cohort

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Healthy volunteers

You may qualify if:

• Age ≥65 years
• Education ≥7 years
• Fluency in the German language
• Written informed consent

You may not qualify if:

• History of cognitive impairment
• Depression
• Severe sensory or motor impairment interfering with cognitive testing
• Serious somatic disease
• Disease or event affecting the central nervous system
• Cerebrovascular disease
• Regular medication with psychoactive drugs except for benzodiazepines
• Participation in a cognitive study within the last 3 months

Sponsors & Collaborators

• Andreas Monsch: lead

MeSH Terms

Conditions

Cognitive Dysfunction; Cognition Disorders; Neurobehavioral Manifestations; Dementia; Alzheimer Disease; Lymphoma, Follicular

Condition Hierarchy (Ancestors)

Neurocognitive Disorders; Mental Disorders; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Brain Diseases; Central Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Alessandra Thomann, MSc

  Felix Platter Hospital Basel

  PRINCIPAL INVESTIGATOR

• Nicolai Goettel, MD

  University Hospital, Basel, Switzerland

  PRINCIPAL INVESTIGATOR

• Raphael Monsch, MD

  University Hospital, Basel, Switzerland

  PRINCIPAL INVESTIGATOR

• Manfred Berres, PhD

  University of Applied Sciences Koblenz

  PRINCIPAL INVESTIGATOR

• Andreas Monsch, PhD

  Felix Platter Hospital Basel

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: PhD

Study Record Dates

• First Submitted: August 8, 2017
• First Posted: August 11, 2017
• Study Start: December 1, 2016
• Primary Completion: April 1, 2017
• Study Completion: April 1, 2017
• Last Updated: May 31, 2018

Record last verified: 2018-05